GSK plc (NYSE:GSK) traded at $33.85 at close of the session on Tuesday, 11/22/22, made an upward move of 1.23% on its previous day’s price.
Looking at the stock we see that its previous close was $33.44 and the beta (5Y monthly) reads 0.29 with the day’s price range being $33.57 – $33.86. The company has a trailing 12-month PE ratio of 14.39. In terms of its 52-week price range, GSK has a high of $47.82 and a low of $28.47. The company’s stock has gained about 6.58% over that past 30 days.
GSK plc has a market cap of $67.51 billion and is expected to release its quarterly earnings report on Feb 01, 2017 – Feb 06, 2017. With its Forward Dividend at 1.63 and a yield of 4.82%, the company’s investors could be anxious for the GSK stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0.96, with the EPS growth for the year raised at $3.46 for 2022 and $3.47 for next year. These figures represent -11.10% and 0.30% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $8.18 billion, with a low of $8.11 billion and a high of $8.26 billion. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $32.53 billion, or -30.70% down from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the GSK stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 21 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 13 have rated the GSK plc (GSK) stock as a Hold, while 7 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the GSK stock currently stands at 1.24, and the current price level is 3.39% off its SMA20 and 7.94% from its 50-day simple moving average. The RSI (14) is pointing at 60.89 while the volatility over the past week is 1.22% and jumps to 1.54% over the past one month. The beta value is 0.70, while the average true range (ATR) is currently pointing at 0.75. The average price target for the stock over the next 12 months is $39.15, with the estimates having a low of $30.37 and a high of $60.03. These price ends are 10.28% and -77.34% off the current price level respectively, although investors could be excited at the prospect of a -12.38% if the GSK share price touches on the median price of $38.04.
Let’s briefly compare GSK plc (GSK) stock to its peers. We find that current price change of 1.23% and -19.47% over the past 12 months for GSK competes that of AstraZeneca PLC (AZN), which has seen its stock price rise 0.87% in the last trading session and was 16.71% over the last one year. Another of its peers Sanofi (SNY) has gained 0.69% previous session, and was -9.36% down over the past year, while Pfizer Inc. (PFE) was also up 1.87% in the last session, while its price remained in the red at -4.14% over the same period. GSK plc has a P/E ratio of 14.39 compared to AstraZeneca PLC’s 101.07 and Sanofi’s 17.10. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.36% and 1.18%, respectively, at close of the trading.
Coming back to GSK plc (NYSE:GSK), we note that the average 3-month trading volume was 6.40 million, while that of the preceding 10-day period stands at 5.72 million. Current shares outstanding are 2.04 billion.
The insiders hold 0.20% of the company’s shares while institutions hold 13.90%. The data shows that short shares as of Oct 13, 2022, stood at 15.87 million at a short ratio of 2.3. This represents a 0.78% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 13.97 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -24.60% down in year-to-date price movement.